Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin

  • Younsoo Bae
  • , Rita A. Buresh
  • , Tracy P. Williamson
  • , Tze Haw Howard Chen
  • , Darin Y. Furgeson

Producción científica: Articlerevisión exhaustiva

28 Citas (Scopus)

Resumen

An intelligent biosynthetic nanobiomaterial (IBN) platform was explored for drug delivery applications for hyperthermic combination chemotherapy and thermal drug targeting. Geldanamycin (GA), a heat shock protein 90 inhibitor, was conjugated to novel thermosensitive poly(K)8-poly(VPGXG)60 block copolymers [K8-ELP(1-60)] with guest residues as valine, alanine and glycine in a 5:2:3 ratio at the 'X' position. The conjugates were completely soluble in PBS and showed a characteristic thermosensitive inverse phase transition. [K8-ELP(1-60)]-GA conjugate nanoparticles showed a size ranging from 50 to 200 nm depending upon temperature. Relevant to systemic drug delivery in vivo, these IBNs stably disperse in aqueous solution. Cytotoxicity assays have shown that the IBN from [K8-ELP(1-60)]-GA conjugates exhibits effective hyperthermic combination chemotherapy with facile heat modulation.

Idioma originalEnglish
Páginas (desde-hasta)16-23
Número de páginas8
PublicaciónJournal of Controlled Release
Volumen122
N.º1
DOI
EstadoPublished - sept 11 2007

Nota bibliográfica

Funding Information:
We thank Prof. Ashutosh Chilkoti (Duke University) for kindly providing the ELP(1-30) gene and Prof. Glen Kwon (University of Wisconsin-Madison) for use of the NICOMP DLS. This work was funded by University of Wisconsin-Madison start-up funds to DYF. This work was graciously supported by the 2007 PhRMA Foundation Research Starter Grant awarded to DYF.

Financiación

We thank Prof. Ashutosh Chilkoti (Duke University) for kindly providing the ELP(1-30) gene and Prof. Glen Kwon (University of Wisconsin-Madison) for use of the NICOMP DLS. This work was funded by University of Wisconsin-Madison start-up funds to DYF. This work was graciously supported by the 2007 PhRMA Foundation Research Starter Grant awarded to DYF.

Financiadores
Pharmaceutical Research and Manufacturers of America Foundation
University of Wisconsin-Madison

    ASJC Scopus subject areas

    • Pharmaceutical Science

    Huella

    Profundice en los temas de investigación de 'Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin'. En conjunto forman una huella única.

    Citar esto